Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430442 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,026
- Enrollment target
NCT01430442: Completed Phase 2 study, sponsored by Pfizer.
NCT01430442 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,026 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (671% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430442, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,026 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.
Primary Outcome
Pain freedom was defined as participants reporting a value of "none" on the four-point numeric rating scale (none=0, mild =1, moderate =2, severe =3) from baseline. Participants with baseline moderate pain or severe pain were included in the analysis.
Interventions
- DRUG Placebo
- DRUG Rimegepant
- DRUG Sumatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,026 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01430442 record still lists
NCT01430442 is an interventional study that assigns participants to a tested intervention. Its 1,026 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (671% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01430442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01430442 about?
NCT01430442 is a clinical study titled "Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine". The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, m...
What is the current status of trial NCT01430442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,026 participants. The study started on 2011-10. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01430442?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG), Sumatriptan (DRUG).
Who is sponsoring clinical trial NCT01430442?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01430442's enrollment target sits among peer trials
1,026 25th of 2000 higher than 1,976 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia